Current treatment challenges
Current treatment options are limited to expensive and invasive anti-VEGF injections. These are only suitable for cases of advanced Wet AMD, and simply address complications associated with the disease.
It is within this scenario that Ellex has prioritized investment into comprehensive clinical investigations to develop 2RT™ as an intervention for AMD in its early stages before patients have progressed to the advanced stage of Wet AMD. With Ellex 2RT™, we have the potential to intervene at the level of the underlying pathology.
With the development of Ellex 2RT™, which utilizes an ultra-short nanosecond laser pulse that's uniquely different to existing retinal laser treatments, it may be possible to treat the compromised retinal pigment epithelium (RPE) and Bruch’s Membrane — the structures responsible for transporting the energy supply to, and removing the waste from, the retinal photoreceptors.
2RT™ represents a breakthrough in the treatment of AMD by stimulating the body’s natural healing process to promote cellular rejuvenation
Earlier treatment to slow AMD
Clinical results show that Ellex 2RT™ offers the potential to slow the rate of progression of macular degeneration— providing a significant breakthrough in treatment strategy for the early stages for AMD.1, 2
1. Jobling et al., “Nanosecond Laser Therapy Reverses Pathologic and Molecular Changes in Age-Related Macular Degeneration without Retinal Damage,” The FASEB Journal 29, no. 2 (February 1, 2015): 696–710, doi:10.1096/fj.14-262444.
2. Guymer, R.H., et al., Nanosecond-laser application in intermediate AMD – 12-month results of fundus appearance and macular function. Clin Experiment Ophthalmol. 2013 Oct 3. doi: 10.1111/ceo.12247.
your primary online resource for Age-Related Macular Degeneration and 2RT™
primary online resource for physicians, for patient marketing and practice development materials